Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts - PubMed (original) (raw)

. 2002 Jan;282(1):C172-82.

doi: 10.1152/ajpcell.00048.2001.

Affiliations

• PMID: 11742810
• DOI: 10.1152/ajpcell.00048.2001

Free article

Differential expression of TGF-beta isoforms by normal and inflammatory bowel disease intestinal myofibroblasts

B C McKaig et al. Am J Physiol Cell Physiol. 2002 Jan.

Free article

Abstract

Intestinal strictures are frequent in Crohn's disease but not ulcerative colitis. We investigated the expression of transforming growth factor (TGF)-beta isoforms by isolated and cultured primary human intestinal myofibroblasts and the responsiveness of these cells and intestinal epithelial cells to TGF-beta isoforms. Normal intestinal myofibroblasts released predominantly TGF-beta(3) and ulcerative colitis myofibroblasts expressed both TGF-beta(1) and TGF-beta(3), whereas in myofibroblast cultures from fibrotic Crohn's disease tissue, there was significantly lower expression of TGF-beta(3) but enhanced release of TGF-beta(2). These distinctive patterns of TGF-beta isoform release were sustained through several myofibroblast passages. Proliferation of Crohn's disease myofibroblasts was significantly greater than that of myofibroblasts derived from normal and ulcerative colitis tissue. In contrast to cells from normal and ulcerative colitis tissue, neutralization of the three TGF-beta isoforms did not affect the proliferation of Crohn's disease intestinal myofibroblasts. Studies on the effect of recombinant TGF-beta isoforms on epithelial restitution and proliferation suggest that TGF-beta(2) may be the least effective of the three isoforms in intestinal wound repair. In conclusion, the enhanced release of TGF-beta(2) but reduced expression of TGF-beta(3) by Crohn's disease intestinal myofibroblasts, together with their enhanced proliferative capacity, may lead to the development of intestinal strictures.

PubMed Disclaimer

Similar articles

• Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease.
  McKaig BC, McWilliams D, Watson SA, Mahida YR. McKaig BC, et al. Am J Pathol. 2003 Apr;162(4):1355-60. doi: 10.1016/S0002-9440(10)63931-4. Am J Pathol. 2003. PMID: 12651627 Free PMC article.
• Expression of transforming growth factor (TGF)-beta1, -beta2, and -beta3 isoforms and TGF-beta type I and type II receptors in multiple sclerosis lesions and human adult astrocyte cultures.
  De Groot CJ, Montagne L, Barten AD, Sminia P, Van Der Valk P. De Groot CJ, et al. J Neuropathol Exp Neurol. 1999 Feb;58(2):174-87. doi: 10.1097/00005072-199902000-00007. J Neuropathol Exp Neurol. 1999. PMID: 10029100
• Transforming growth factors beta1, beta2 and beta3 and their receptors are differentially expressed in human peritoneal fibroblasts in response to hypoxia.
  Saed GM, Collins KL, Diamond MP. Saed GM, et al. Am J Reprod Immunol. 2002 Dec;48(6):387-93. doi: 10.1034/j.1600-0897.2002.01090.x. Am J Reprod Immunol. 2002. PMID: 12607775
• TGF beta -1, -2 and -3 in the modulation of fibrosis in the cornea and other organs.
  Wilson SE. Wilson SE. Exp Eye Res. 2021 Jun;207:108594. doi: 10.1016/j.exer.2021.108594. Epub 2021 Apr 22. Exp Eye Res. 2021. PMID: 33894227 Review.
• The fate of myofibroblasts during the development of fibrosis in Crohn's disease.
  Li C, Kuemmerle JF. Li C, et al. J Dig Dis. 2020 Jun;21(6):326-331. doi: 10.1111/1751-2980.12852. J Dig Dis. 2020. PMID: 32092217 Review.

Cited by

• Eosinophils mitigate intestinal fibrosis while promoting inflammation in a chronic DSS colitis model and co-culture model with fibroblasts.
  Jacobs I, Deleu S, Ke BJ, Cremer J, Dilissen E, De Hertogh G, Martens T, Vanden Berghe P, Matteoli G, Vermeire S, Breynaert C, Vanuytsel T, Verstockt B. Jacobs I, et al. Sci Rep. 2024 Nov 7;14(1):27133. doi: 10.1038/s41598-024-78602-0. Sci Rep. 2024. PMID: 39511371 Free PMC article.
• Mechanisms and therapeutic research progress in intestinal fibrosis.
  Liu Y, Zhang T, Pan K, Wei H. Liu Y, et al. Front Med (Lausanne). 2024 Jun 14;11:1368977. doi: 10.3389/fmed.2024.1368977. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38947241 Free PMC article.
• Fibrostenosing Crohn's Disease: Pathogenetic Mechanisms and New Therapeutic Horizons.
  Mignini I, Blasi V, Termite F, Esposto G, Borriello R, Laterza L, Scaldaferri F, Ainora ME, Gasbarrini A, Zocco MA. Mignini I, et al. Int J Mol Sci. 2024 Jun 7;25(12):6326. doi: 10.3390/ijms25126326. Int J Mol Sci. 2024. PMID: 38928032 Free PMC article. Review.
• Differential expression of small bowel TGFβ1 and TGFβ3 characterizes intestinal strictures in patients with fibrostenotic Crohn's disease.
  Levitte S, Khan I, Iyahen V, Ziai J, Gubatan J, Sheng R, Glickstein SB, Sun T, Park KT, McBride J, Keir M. Levitte S, et al. Histochem Cell Biol. 2024 Sep;162(3):225-230. doi: 10.1007/s00418-024-02290-0. Epub 2024 May 5. Histochem Cell Biol. 2024. PMID: 38705911
• Fibrostricturing Crohn's Disease Is Marked by an Increase in Active Eosinophils in the Deeper Layers.
  Jacobs I, Ke BJ, Ceulemans M, Cremer J, D'Hoore A, Bislenghi G, Matteoli G, De Hertogh G, Sabino J, Ferrante M, Vermeire S, Breynaert C, Vanuytsel T, Verstockt B. Jacobs I, et al. Clin Transl Gastroenterol. 2024 Jul 1;15(7):e00706. doi: 10.14309/ctg.0000000000000706. Clin Transl Gastroenterol. 2024. PMID: 38690831 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information